GlassScriptPhysician profile
Carlos J Sandoval
NPI 1780625822
$6,701.57
in general payments reported to CMS, 2019-2025
21 companies · $898 in 2025
The $898 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $986 · 2021: $1,148 · 2022: $705 · 2023: $1,021 · 2024: $1,185 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.43 | 2021-2025 | Vraylar |
| Lundbeck LLC | $745.03 | 2020-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $673.60 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Allergan, INC. | $660.54 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $562.82 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $480.21 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $464.69 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $340.78 | 2023-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $319.23 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $314.66 | 2022-2024 | Spravato, Invega Sustenna |
| Merck Sharp & Dohme LLC | $104.21 | 2022-2023 | Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $104.18 | 2025 | Cobenfy |
| Biogen, INC. | $91.98 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.15 | 2022-2025 | Caplyta |
| Emd Serono, INC. | $40.00 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $30.27 | 2023 | Ingrezza |
| Indivior INC. | $24.41 | 2020 | |
| Idorsia Pharmaceuticals US INC | $17.52 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $17.05 | 2023 | Hetlioz, Fanapt |
| Shire North American Group INC | $16.11 | 2019 | |
| Adlon Therapeutics L.P. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Sandoval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.